Henry K Kwan

Title: Henry K Kwan: Innovator in Pharmaceutical Compositions

Introduction

Henry K Kwan is a notable inventor based in Summit, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage compositions. With a total of 3 patents to his name, Kwan's work has had a meaningful impact on the treatment of upper respiratory diseases.

Latest Patents

Kwan's latest patents include a stable extended release oral dosage composition comprising loratadine. This innovative film-coated extended release oral dosage composition contains the nasal decongestant pseudoephedrine sulfate in a unique polymer matrix core. The film-coating on this core includes the non-sedating antihistamine, loratadine, which is used for treating patients exhibiting signs and symptoms associated with upper respiratory diseases and nasal congestion. Another significant patent involves biologically stable interferon compositions comprising thimerosal. This patent describes stable pharmaceutical compositions that include interferon and thimerosal, which are substantially resistant to microorganism contamination and growth.

Career Highlights

Henry K Kwan is associated with Schering Corporation, where he has been instrumental in advancing pharmaceutical innovations. His work has contributed to the development of effective treatments that enhance patient care and improve health outcomes.

Collaborations

Kwan has collaborated with Stephen M Liebowitz, further enriching his research and development efforts in the pharmaceutical industry.

Conclusion

Henry K Kwan's contributions to pharmaceutical compositions demonstrate his commitment to innovation and improving healthcare solutions. His patents reflect a deep understanding of the complexities involved in drug formulation and patient treatment.